Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin.

× No keyword cloud information.

19 in total

1. Immune globulin subcutaneous (human), 20% liquid.

Authors:
Journal: P T Date: 2010-08

2. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.

Authors: Sylvain Thépot; Marion Malphettes; Anaëlle Gardeur; Lionel Galicier; Bouchra Asli; Lionel Karlin; Laurence Gérard; Richard Laumont; Marie-Laure Doize; Bertrand Arnulf; Claire Fieschi; Djaouïda Bengoufa; Eric Oksenhendler
Journal: J Clin Immunol Date: 2010-07 Impact factor: 8.317

3. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.

Authors: Ann Gardulf; Uwe Nicolay; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz Costa Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Jaune Pons; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal: J Clin Immunol Date: 2006-04-26 Impact factor: 8.317

Review 4. Intravenous immunoglobulin in immunodeficiency states: state of the art.

Authors: Elias Toubi; Amos Etzioni
Journal: Clin Rev Allergy Immunol Date: 2005-12 Impact factor: 8.667

5. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.

Authors: Richard L Wasserman; Isaac Melamed; Lisa Kobrynski; Steven D Strausbaugh; Mark R Stein; Marlies Sharkhawy; Werner Engl; Heinz Leibl; Luba Sobolevsky; David Gelmont; Richard I Schiff; William J Grossman
Journal: J Clin Immunol Date: 2011-03-22 Impact factor: 8.317

Review 6. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors: Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal: J Clin Immunol Date: 2012-06-23 Impact factor: 8.317

7. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors: Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal: Ther Clin Risk Manag Date: 2010-02-02 Impact factor: 2.423

8. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.

Authors: Akhilesh Chouksey; Kimberly Duff; Nancy Wasserbauer; Melvin Berger
Journal: Allergy Asthma Clin Immunol Date: 2005-09-15 Impact factor: 3.406

9. Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study.

Authors: Clementina Canessa; Vera Gallo; Claudio Pignata; Antonino Trizzino; Simona Graziani; Baldassarre Martire; Viviana Moschese; Valentina Palladino; Giorgio Maria Boggia; Andrea Matucci; Antonio Pecoraro; Giuseppe Spadaro; Alessandra Vultaggio; Chiara Azzari
Journal: Pediatr Allergy Immunol Pulmonol Date: 2019-06-17 Impact factor: 1.349

10. Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors: Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal: Am Health Drug Benefits Date: 2019-10